KFI
GLOBALLY RECOGNIZED VETERINARY CROThe KFI ADVANTAGE
With KFI, your research will meet all clinical and regulatory requirements, and deliver results based on GLP and GCP processes and standards.
SERVICES
Our core business is delivering the highest quality Safety, Efficacy or Pharmacology studies available in the veterinary clinical research industry.
ANNOUNCEMENTS
Whether its new staff, a new clinical research study or a new innovation, stay up to date with all that’s going on at KFI.
Stay up to date with KFI
KFI Conducted Feline TASS for Solensia® now Approved by FDA
A year ago, KFI announced the approval of Solensia® to Zoetis by the European Commission. We are now happy to report that this unique treatment for feline osteoarthritic pain, has been approved by CVM. This is the first monoclonal antibody new...
KFI is Excited to Announce the Conditional Approval of Panoquell-CA1 by CVM
The first ever drug available for treating acute onset pancreatitis in dogs, Panoquell-CA1 (fuzapladib sodium), just received conditional approval by CVM. Sponsored by Ishihara Sangyo Kaisha, Ltd, KFI carried out the TASS for this injectable drug....
Coming in January of 2023 – Canine Dental Studies at KFI
KFI staff are in training to run dental studies as per the Veterinary Oral Health Council (VOHC) standards. The VOHC oversees and approves dental products aimed at reducing build-up of plaque and tartar on teeth. Dr. Andrew Oster DVM, Director of...
KFI Conducted Feline TASS for Solensia® now Approved by FDA
A year ago, KFI announced the approval of Solensia® to Zoetis by the European Commission. We are now happy to report that this unique treatment for feline osteoarthritic pain, has been approved by CVM. This is the first monoclonal antibody new...
KFI is delighted to announce the approval of Carprofen and Deracoxib Chewable tablets by the FDA’s Center for Veterinary Medicine for Felix Pharmaceuticals Pvt. Ltd.
On June 14, 2021 Deracoxib Chewable tablets were approved for use in dogs for the treatment of pain and inflammation associated with OA, postoperative orthopedic surgery and dental surgery. On June 28, 2021, Carprofen Chewable tablets were approved...
KFI Construction Announcement
KFI is delighted to announce that construction on the new canine and feline housing, enrichment and procedural space has been completed and has passed the OMAFRA licensing inspection required for research facilities in Ontario to operate. The 5,000...
KFI conducts feline Target Animal Safety study for Solensia® (frunevetmab).
Solensia® is the first feline injectable mAB designed specifically for cats suffering from pain associated with osteoarthritis. The European Commission granted Zoetis Inc. the marketing authorization on Feb. 22, 2021. This once monthly feline...
KFI performs the pharmacokinetic work for FDA approved ELURA™
FDA’s Center for Veterinary Medicine approved Elanco US Inc.’s NADA for ELURA™ on Oct. 16th, 2020. Elura™ is an oral solution of capromorelin developed for the management of weight loss in cats with chronic kidney disease (CKD). This is the first...
KFI is excited to announce the acquisition of an additional 5,000 sq feet of space as of September 1, 2020.
Construction on new state-of-the art canine and feline housing, enrichment, and procedure space will begin this fall. “Our focus remains to deliver high quality and compassionate science to help change and improve the lives of companion animals”...
KFI carries out the bioequivalence work for FDA approved Enrofloxacin Flavored Tablets for dogs and cats.
FDA’s Center for Veterinary Medicine approved Felix Pharmaceuticals Pvt. Ltd.’s ANADA for Enrofloxacin Flavored Tablets on May 21, 2020. The flavored tablets provide veterinarians with a new treatment option for disease associated with bacteria...